1-5 of 5
Haiping Yang
Close
Sort by
Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Huixing Zhou, Long Chang, Jing Jia, Jie Ma, Hua Xue, Hao Li, Wenrong Huang, Hebing Zhou, Jingnan Sun, Liping Su, Yanping Ma, Huang Hongming, Hongmei Jing, Zhenling Li, Guangyu Ma, Guohong Su, Jihao Zhou, Biyun Chen, LI Bao, Zhihua Zhang, Lin Yang, Haiping Yang, Yanhong Zhao, Chunyan Sun, Qingming Wang, Qimuge Saiyin, Da Gao, Xiaoxia Chu, Zhenfang Xi, Weiwei Tian, Xuliang Shen, Shi Minxia, Jin Zhang, Yi Chen, Jingbo Xu, Yao Liu, Hongling Peng, Weijun Fu, Jun Luo, Zhenyu Li, Hui-Han Wang, Xiaobo Wang, Xiuli Sun, Jinqiao Zhang, Wei WANG, Yan Yan, Yafei Wang, Xin Du, Yonghuai Feng, Yi Wang, Ying Sun, Liye Zhong, Li Gao, Wenming Chen, Jian Li, Wen Gao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4754.
https://doi.org/10.1182/blood-2023-180736
Published: 2023
Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)

Hongyan Tong, Sujun Gao, Wei Yang, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, Haiping Yang, Ronghua Hu, Shaoyuan Wang, Zheng Dong, Yixuan Yang, Zhenjiu Wang, Qiying Lu, Wenzhi Tian, Zhijian Xiao, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1859.
https://doi.org/10.1182/blood-2023-181501
Published: 2023
Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Wei Yang, Sujun Gao, Xiaojing Yan, Rong Guo, Lijie Han, Fei Li, Yafei Wang, Junmin Li, Chunkang Chang, Haiping Yang, Ronghua Hu, Hongyan Tong, Xingli Zhao, Qiubai Li, Jingdong Zhang, Xin Du, Sanfang Tu, Cheng Zhang, Congmeng Lin, Xin Du, Zhenling Li, Ligen Liu, Zhenyu Li, Zheng Dong, Yixuan Yang, Qiying Lu, Wenzhi Tian, Zhijian Xiao
Journal: Blood
Blood (2023) 142 (Supplement 1): 320.
https://doi.org/10.1182/blood-2023-174420
Published: 2023
Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Jie Jin, Huafeng Wang, Wen-Juan Yu, Zheng Ge, Xudong Wei, Yuhua Li, Zhongxing Jiang, Yiqing Li, Xin Du, Linhua Yang, Lie Lin, Jishi Wang, Yazhou Yao, Xiaoping Hu, Jianping Lan, Xiuzhi Deng, Tong Chen, Xianqi Feng, Dengju Li, Ming Hou, Rong Fu, Siyong Huang, Jingbo Wang, Xin Du, Hui Yang, Haiping Yang, Yingzhi Jiang, Zhijie Wang, Deng Li, Bing Liu, Ning Kang, Yulei Zhuang, Yingjun Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4281.
https://doi.org/10.1182/blood-2023-188961
Published: 2023
Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Miao Miao, Depei WU, Shuangfeng Xie, Mei Hong, ChunKang Chang, Li Yu, Sujun Gao, Yan Li, Yuhua Li, Zunmin Zhu, Baolin Tang, Bingzong Li, Haiping Yang, Jishi Wang, Ling Qin, Rong Fu, Fei Li, Liangming Ma, Qifa Liu, Xin Du, Zhongxing Jiang, Zhenyu Li, Aijun Liu, Hongyan Tong, Jun Ma, Li Liu, Qingchi Liu, Yajing Xu, Hui Zhou, Yan Wang, Jianlin Chen, Ziru Niu, Mingxia Chen, Zhijian Xiao
Journal: Blood
Blood (2022) 140 (Supplement 1): 4045–4046.
https://doi.org/10.1182/blood-2022-155901
Published: 2022